FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

FDA OKs Cordis Vascular Closure Device

FDA approves a Cordis PMA for its Mynx Control Venous Vascular Closure Device for use in certain cardiac ablation procedures.

latest-news-card-1
Medical Devices

Dont Use Medtronic NIM EMG Endotracheal Tubes: FDA

FDA cautions healthcare providers and facilities to heed a Medtronic urgent recall of all models and lots of its NIM EMG Contact and Standard endotrac...

latest-news-card-1
Biologics

UniQure Seeking Accelerated Approval Path for Gene Therapy

UniQure says it will meet soon with FDA to discuss potential expedited clinical development pathways and accelerated approval after reporting positive...

latest-news-card-1
Human Drugs

CGMP Violations at S. Koreas ReBom Co.

FDA warns South Koreas ReBom Co. about CGMP violations in its manufacturing of OTC drugs.

latest-news-card-1
Medical Devices

Inspire Recalls Implantable Pulse Generator

Inspire Medical Systems recalls its Inspire IV Implantable Pulse Generator (IPG) Model 3028 due to a manufacturing defect that can disrupt therapy.

latest-news-card-1
Federal Register

Draft Guide on Addressing Product Misinformation

Federal Register notice: FDA makes available a revised draft guidance entitled Addressing Misinformation About Medical Devices and Prescription Drugs:...

latest-news-card-1
Federal Register

Draft Guide on Use-Related Risk Analyses

Federal Register notice: FDA makes available a draft guidance entitled Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products...

latest-news-card-1
Human Drugs

Optikem CGMP Violations Cited

FDA warns Denver, CO-based Optikem about CGMP violations in its production of finished drugs.

latest-news-card-1
Biologics

CBER Updates 2024 Guidance Agenda

CBER publishes an updated 2024 guidance agenda with 20 listings.

latest-news-card-1
Human Drugs

Elevar Resubmitting Cancer Drug NDA

Elevar Therapeutics says that after a meeting with FDA it is ready to resubmit its NDA for rivoceranib in combination with camrelizumab as a first-lin...